Patent US4892741A successfully refreshed from Google Patents.
US4892741A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Press coated DHP tablets
Assignee: Bayer AG
•
Filing: 1988-06-08
•
Granted: 1990-01-09
•
Expires: 2008-06-08
Abstract
Abstract The invention relates to solid pharmaceutical preparations which have a long-lasting action and are for dihydropyridines in the form of a press coated tablet, and a process for their preparation.
Inventors
- 👤 Andreas Ohm
- 👤 Helmut Luchtenberg
- 👤 Shinji Maegata
- 👤 Wolfgang Opitz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 13:10
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2072; A61K9/2086; A61K9/209; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61P; A61P9/00; A61P9/12
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
52 words
A solid medicament preparation having a long-lasting action in the form of a press coated tablet which contains a sparingLy soluble dihydropyridine, the press coated tablet comprising (a) a core which contains a dihydropyridine in rapid-release form, and (b) a coat around the core, the coat containing a dihydropyridine in slow-release form.
Claim 2
Dependent Claim
52 words
A solid medicament preparation having a long-lasting action in the form of a press coated tablet which contains a sparingLy soluble dihydropyridine, the press coated tablet comprising (a) a core which contains a dihydropyridine in rapid-release form, and (b) a coat around the core, the coat containing a dihydropyridine in slow-release form.
Claim 3
Dependent Claim
170 words
A press coated tablet according to claim 1, wherein the dihydropyridine is of the formula ##STR3## in which R 1 represents a phenyl radical which is substituted by one or two identical or different substituents from the group comprising nitro, halogen and trifluoromethyl, or represents a radical from the group comprising ##STR4## ##STR5## R 2 represents a nitro group or the radical COOR 6 , in which R 6 denotes alkyl having 1 to 10 C atoms which is optionally substituted by alkoxy having 1 to 4 C atoms or by one or more halogens, or in which R 2 , together with R 5 , represents the lactone group --CO--O--CH 2 , R 3 represents alkyl having 1 to 10 C atoms, which is optionally substituted by alkoxy having 1 to 4 C atoms or by one or more fluorine atoms and R 4 and R 5 are identical or different and in each case represent alkyl having 1 to 4 C atoms, which is optionally substituted by hydroxyl.
Claim 4
Dependent Claim
32 words
A press coated tablet according to claim 1, containing about 5 to 50% of the total dihydropyridine in the core and about 95 to 50% of the total dihydropyridine in the coat.
Claim 5
Dependent Claim
32 words
A press coated tablet according to claim 1, containing about 10 to 40% of the total dihydropyridine in the core and about 90 to 60% of the total dihydropyridine in the coat.
Claim 6
Dependent Claim
30 words
A press coated tablet according to claim 1, wherein the core contains the dihydropyridine in amorphous form or in crystalline form having a maximum mean particle size of 25 μm.
Claim 7
Dependent Claim
23 words
A press coated tablet according to claim 1, wherein about 10 to 99% of the total coat weight is a hydrophilic gel-forming polymer.
Claim 8
Dependent Claim
23 words
A press coated tablet according to claim 6, wherein the coat contains methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose and/or sodium carboxymethylcellulose as the hydrophilic gel-forming polymer.
Claim 9
Dependent Claim
18 words
A press coated tablet according to claim 7, wherein the coat contains hydroxypropylcellulose as the hydrophilic gel-forming polymer.
Claim 10
Dependent Claim
27 words
A press coated tablet according to claim 1, wherein the dihydropyridine comprises at least one compound selected from the group consisting of nifedipine, nitrendipine, nimodipine and nisoldipine.
Claim 11
Dependent Claim
32 words
A press coated tablet according to claim 1, wherein the core contains the dihydropyridine in crystalline form and further contains at least one of a readily water-soluble auxiliary, disintegrant and wetting agent.
Claim 12
Dependent Claim
22 words
A press coated tablet according to claim 1, wherein the coating is itself coated with a layer of dihydropyridine in rapid-release form.
Claim 13
Dependent Claim
178 words
A process for manufacturing solid medicament preparations having a long lasting action containing a sparingly soluble dihydropyridine in form of a press coated tablet comprising: (a) a core which contains a dihydropyridine in rapid-release form, and (b) a coat around the core, the coat containing a dihydropyridine in slow-release form, the core having been produced by mixing the active substance and a filler, granulating this mixture by adding an aqueous solution of binder, drying and sieving the granulate, adding a lubricant and pressing to form the core, or forming the core by direct compression or by roller compaction plus compression, producing the granule for the coat by spraying an aqueous suspension containing the active substance and a binder on the solid ingredients, drying and sieving, mixing with a lubricant, press coating the granules for the coat upon the core, and optionally film coating the obtained press coated tablet with lacquers which optionally contain a small amount of the active substance up to a maximum of 20% of the total amount of the active substance in the whole composition.
Claim 14
Dependent Claim
178 words
A process for manufacturing solid medicament preparations having a long lasting action containing a sparingly soluble dihydropyridine in form of a press coated tablet comprising: (a) a core which contains a dihydropyridine in rapid-release form, and (b) a coat around the core, the coat containing a dihydropyridine in slow-release form, the core having been produced by mixing the active substance and a filler, granulating this mixture by adding an aqueous solution of binder, drying and sieving the granulate, adding a lubricant and pressing to form the core, or forming the core by direct compression or by roller compaction plus compression, producing the granule for the coat by spraying an aqueous suspension containing the active substance and a binder on the solid ingredients, drying and sieving, mixing with a lubricant, press coating the granules for the coat upon the core, and optionally film coating the obtained press coated tablet with lacquers which optionally contain a small amount of the active substance up to a maximum of 20% of the total amount of the active substance in the whole composition.
References Cited (Backward Citations)
US3184386A
Cited
GB1144915A
Cited
US3558768A
Cited
FR2331375A1
Cited
US4765990A
Cited
GB2123291A
Cited
US4654206A
Cited
US4803081A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-01-08 | 1993-07-10 | 1994-01-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-01-08 | 1997-07-10 | 1998-01-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-01-08 | 2001-07-10 | 2002-01-09 | $7700.00 | Window Closed / Lapsed |